Hakan ATALAR, Kerem BAŞARIR, HÜSEYİN YUSUF YILDIZ, Yener SAĞLIK

Ekstremite yerleşimli malign fibröz histiyositomlu hastalarda prognostik faktörler

Amaç: Ekstremite yerleşimli malign fibröz histiyositomlu olgularda prognostik faktörler araştırıldı. Çalışma planı: Çalışmada ekstremite yumuşak doku malign fibröz histiyositom tanısı konan 26 hasta (22 erkek, 4 kadın; 15 hasta

Anahtar Kelimeler:

Seyir, Histiyositom, iyi huylu fibröz, Yumuşak doku neoplazileri, Ekstremiteler, Neoplazm metastazı, Neoplazm nüksü, lokal, Sağkalım analizi, Radyoterapi, adjuvan

Prognostic factors in patients with malignant fibrous histiocytoma of the extremities

Objectives: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity. Methods: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity. Clinical and pathological data were analyzed including age, gender, affected extremity, presentation status (primary or recurrent), localization (proximal or distal), size, depth, and grade of the tumor, resection quality, adjuvant therapy, and the presence of distant metastasis at the time of diagnosis. Results: The mean follow-up of 16 patients who were alive was 44.8 months (range 24 to 120 months). The mean symptom duration before diagnosis was seven months (range 1 to 26 months). All the patients underwent surgical resection. A margin-negative R0 resection was obtained in 17 patients. Amputation was performed in seven patients. Adjuvant chemotherapy and radiotherapy were administered to 17 patients and 10 patients, respectively. Local recurrence was detected in eight patients. Two patients had distant metastasis at the time of diagnosis while eight patients developed distant metastasis within a mean of 13 months (range 7 to 20 months) postoperatively. Kaplan-Meier analysis showed an overall five-year survival rate of 61.5%, being 100% in low-grade tumors, and 28.2% in high-grade tumors. Tumor grade was the only significant parameter affecting survival in both univariate (p=0.004) and multivariate (p=0.023) analyses. Conclusion: Patients with high-grade malignant fibrous histiocytoma have a poorer prognosis

Keywords:

Prognosis, Histiocytoma, Benign Fibrous, Soft Tissue Neoplasms, Extremities, Neoplasm Metastasis, Neoplasm Recurrence, Local, Survival Analysis, Radiotherapy, Adjuvant,

PDF

___

1. Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Malignant fibrous histiocytoma of the extremity. Cancer 1999;85:1765-72.
2. Bravo PA, Mena VD, Chicharro E. Malignant fibrous histiocytoma of bone treated by resection and prosthesis: a case report. Int Orthop 1983;7:105-11.
3. Huvos AG, Heilweil M, Bretsky SS. The pathology of malignant fibrous histiocytoma of bone. A study of 130 patients. Am J Surg Pathol 1985;9:853-71.
4. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 1996;77:1823-30.
5. Campanacci M, Bertoni F, Bacchini P, editors. Bone and soft tissue tumors. Notini S, translator. Translation of “Tumori delle ossa e delle parti molli”. New-York: Springer-Verlag; 1990. p. 885-901.
6. Peiper M, Zurakowski D, Knoefel WT, Izbicki JR. Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 2004;135:59-66.
7. Pritchard DJ, Reiman HM, Turcotte RE, Ilstrup DM. Malignant fibrous histiocytoma of the soft tissues of the trunk and extremities. Clin Orthop Relat Res 1993;(289):58-65.
8. Robert KH. Malignant tumors of bone. In: Canale ST, editor. Campbell’s operative orthopaedics. Vol, 1. 10th ed. St. Louis: Mosby; 2003. p. 827-58.
9. Akerman M. Malignant fibrous histiocytoma-the commonest soft tissue sarcoma or a nonexistent entity? Acta Orthop Scand Suppl 1997;273:41-6.
10. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Semin Diagn Pathol 1995;12:210-20.
11. Lee SY, Kim SS, Jeon DG, Baek GH. Malignant fibrous histiocytoma of the limbs. Int Orthop 1993;17:173-5.
12. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982;49:1721-33.
13. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-75.
14. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. American Joint Committee on Cancer: Cancer staging manual. 6th ed. New York: Springer; 2002.
15. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41:2250-66.
16. Berlin O, Stener B, Angervall L, Kindblom LG, Markhede G, Oden A. Surgery for soft tissue sarcoma in the extremities. A multivariate analysis of the 6-26-year prognosis in 137 patients. Acta Orthop Scand 1990;61:475-86.
17. Bramwell VH, Santoro A, Rouesse J, Mouridsen H, Steward W, Van Oosterom A, et al. Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer. Semin Surg Oncol 1988;4:45-52.
18. Enzinger FM, Weiss SW, editors. Malignant fibrohistiocytic tumors. In: Soft tissue tumors. 2nd ed. St. Louis: Mosby; 1988. p. 252-73.
19. Peabody TD, Monson D, Montag A, Schell MJ, Finn H, Simon MA. A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities. J Bone Joint Surg [Am] 1994;76:1167-73.
20. Yurdoğlu C, Enson C, Altun M, Şahlan S, Yalaman O. Ekstremite yumuşak doku sarkomlarında lokal rezeksiyonlar. Acta Orthop Traumatol Turc 1994;28:113-5.
21. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003;21:2719-25.
22. Yildiz C, Erler K, Bilgic S, Atesalp AS, Basbozkurt M. The effects of surgical margins on local control and survival in extremity soft tissue sarcomas. [Article in Turkish] Acta Orthop Traumatol Turc 2003;37:359-67.
23. Sadoski C, Suit HD, Rosenberg A, Mankin H, Efird J. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-30.
24. Leow AM, Halim AS, Wan Z. Reconstructive treatment following resection of high-grade soft-tissue sarcomas of the lower limb. J Orthop Surg 2005;13:58-63.
25. Brennan MF, Hilaris B, Shiu MH, Lane J, Magill G, Friedrich C, et al. Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch Surg 1987;122:1289-93.
26. Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol 2004;43:530-5.
27. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
28. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt- Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-49.